ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

2019 Refined Criteria for Cirrhotic Cardiomyopathy Predict Post Liver Transplant Cardiac Events

M. J. Izzy1, A. Soldatova2, X. Sun2, M. Angirekula3, K. Mara4, G. Lin2, K. Watt3

1Gastroenterology and Hepatology, Vanderbilt University Medical Center, Nashville, TN, 2Cardiovascular Medicine, Mayo Clinic, Rochester, MN, 3Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, 4Health Sciences Research, Mayo Clinic, Rochester, MN

Meeting: 2020 American Transplant Congress

Abstract number: 50

Keywords: Heart, Liver, Liver cirrhosis, Outcome

Session Information

Date: Saturday, May 30, 2020

Session Name: Liver: Portal Hypertension and Other Complications of Cirrhosis

Session Time: 3:15pm-4:45pm

 Presentation Time: 3:51pm-4:03pm

Location: Virtual

Related Abstracts
  • Stress Cardiomyopathy in the Perio-Perative Period After Liver Transplant.
  • Pre-Transplant Cardiac Work Up Does Not Predict Post-Transplant Cardiac Events at One Year among Kidney and Pancreas Transplant Recipients

*Purpose: Cirrhotic cardiomyopathy (CCM) encompasses systolic ± diastolic dysfunction (DD) in patients with end stage liver disease in the absence of known cardiac disease. The echocardiographic criteria for CCM were recently revised to reflect the advancement in echocardiographic technology. This study evaluates the prevalence of CCM, per the new criteria, and its impact on post transplant outcomes.

*Methods: This is a retrospective matched cohort study of liver transplant (LT) recipients between 01/2008 and 11/2017. Three cohorts with decompensated cirrhosis (due to non-alcoholic steatohepatitis, alcoholic liver disease, or other etiologies) were matched based on age (± 5 years), sex, and year of transplant (± 5 years) after excluding patients listed without evidence of hepatic decompensation. Clinical and echocardiographic data were collected. CCM was defined as having diastolic dysfunction, left ventricular ejection fraction <50%, and/or global longitudinal strain>-18%. Major cardiovascular events (MACE) included coronary artery disease (CAD), congestive heart failure (HF), atrial and ventricular dysrhythmia, and stroke. Descriptive analyses were performed.

*Results: 59/141 patients were females. The mean age at LT was 57.8 (±7.6) years. The prevalence of pre LT advanced (i.e. stage 2 or 3) DD was 18.4%. To eliminate non-CCM causes of advanced diastolic dysfunction, prevalence was re-calculated after adjustment for diabetes mellitus, aging, and hypertension and it was 17.7%. DD with indeterminate stage was 14.7%. Ejection fraction was > 50% in all patients reflecting transplant selection criteria. GLS was impaired in 1.7%. The prevalence of CCM was 32.8%. CCM was associated with increased risk of developing MACE after transplant (HR 2.51 (1.13-5.57), p 0.02, figure). There was a trend towards decreased risk for CHF > 3 months after LT in patients with normal diastolic function compared to DD (HR 0.30 (0.08-1.13), p 0.07).

*Conclusions: Cirrhotic cardiomyopathy, defined by abnormal myocardial strain and/or abnormal diastolic function, affects approximately one third of LT candidates. CCM is associated with increased risk for major cardiovascular events following liver transplant. Further studies are needed to validate these findings and evaluate the impact of post LT echocardiographic surveillance.

 border=

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Izzy MJ, Soldatova A, Sun X, Angirekula M, Mara K, Lin G, Watt K. 2019 Refined Criteria for Cirrhotic Cardiomyopathy Predict Post Liver Transplant Cardiac Events [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/2019-refined-criteria-for-cirrhotic-cardiomyopathy-predict-post-liver-transplant-cardiac-events/. Accessed January 15, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • How To Handle a Missed or Delayed Dose Intake? A Pharmacokinetic Study of Cyclosporine and Tacrolimus in Renal Transplant Patients
  • Hyperkalemia in the Early Post Renal Transplant Period
  • Direct Oral Anticoagulation Use in Kidney Transplant Recipients

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.